Deletion of the GI-2 integrase and the wbkA flanking transposase improves the stability of Brucella melitensis Rev 1 vaccine by Mancilla, Marcos et al.
VETERINARY RESEARCH
Mancilla et al. Veterinary Research 2013, 44:105
http://www.veterinaryresearch.org/content/44/1/105RESEARCH Open AccessDeletion of the GI-2 integrase and the wbkA
flanking transposase improves the stability of
Brucella melitensis Rev 1 vaccine
Marcos Mancilla1,2, María-Jesús Grilló3, María-Jesús de Miguel4, Ignacio López-Goñi1, Beatriz San-Román3,
Ana Zabalza-Baranguá3 and Ignacio Moriyón1*Abstract
Brucella melitensis Rev 1 is the best vaccine available for the prophylaxis of small ruminant brucellosis and, indirectly,
for reducing human brucellosis. However, Rev 1 shows anomalously high rates of spontaneous dissociation from
smooth (S) to rough (R) bacteria, the latter being inefficacious as vaccines. This S-R instability results from the loss of
the O-polysaccharide. To overcome this problem, we investigated whether some recently described mechanisms
promoting mutations in O-polysaccharide genes were involved in Rev 1 S-R dissociation. We found that a
proportion of Rev 1 R mutants result from genome rearrangements affecting the wbo O-polysaccharide loci of
genomic island GI-2 and the wbkA O-polysaccharide glycosyltransferase gene of the wbk region. Accordingly, we
mutated the GI-2 int gene and the wbk IS transposase involved in those arrangements, and found that these Rev 1
mutants maintained the S phenotype and showed lower dissociation levels. Combining these two mutations
resulted in a strain (Rev 2) displaying a 95% decrease in dissociation with respect to parental Rev 1 under conditions
promoting dissociation. Rev 2 did not differ from Rev 1 in the characteristics used in Rev 1 typing (growth rate,
colonial size, reactivity with O-polysaccharide antibodies, phage, dye and antibiotic susceptibility). Moreover, Rev 2
and Rev 1 showed similar attenuation and afforded similar protection in the mouse model of brucellosis vaccines.
We conclude that mutations targeting genes and DNA sequences involved in spontaneous O-polysaccharide loss
enhance the stability of a critical vaccine phenotype and complement the empirical stabilization precautions taken
during S Brucella vaccine production.Introduction
The members of the genus Brucella are gram-negative
bacteria that cause brucellosis, an infection affecting do-
mestic and wild animals as well as human beings. The
genus includes several species among which B. melitensis,
B. abortus and B. suis are the main cause of brucellosis
in domestic livestock. B. melitensis preferentially infects
sheep and goats and represents the most common cause
of human brucellosis, a severe and debilitating disease
endemic in large areas of Africa, the Middle East, Asia
and Latin America [1]. This distribution reflects the
problems associated with the control and eradication of
a zoonotic disease in areas where extensive breeding* Correspondence: imoriyon@unav.es
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reproduction in any medium, provided the orand infrastructure weaknesses are combined. Accord-
ingly, the World Health Organization has classified bru-
cellosis as one of the top neglected zoonosis, a group of
diseases that hamper development and contribute to
the perpetuation of poverty [2].
The most effective measure to control brucellosis is the
vaccination of the host ruminants [3]. Several vaccines
have been developed for this purpose but the smooth (S)
attenuated B. abortus S19 and B. melitensis Rev 1 strains
are superior in controlled experiments [4-6] and the only
ones that have proved their usefulness in successful eradi-
cation programs. Human-to-human contagion is only an-
ecdotal, and there is abundant evidence showing that the
correct use of vaccine Rev 1 results in a parallel decrease
of human brucellosis, as illustrated by the experience in
Greece [7]. Indeed, the use of a vaccine of good quality is
essential and, in this regard, Rev 1 is not lacking problems.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Rev 1 has a marked tendency to undergo the smooth-
rough (S-R) dissociation that results in a dominancy of
non-immunogenic R mutants that make the vaccine inef-
fective [8]. Indeed, procedures that minimize the S-R dis-
sociation and controls to exclude batches containing R
bacteria are critical in Rev 1 production [8].
In the brucellae, the S-R dissociation is caused by
the spontaneous mutations leading to the loss of the
O-polysaccharide (O-PS) of the outer membrane lipopoly-
saccharide (LPS). The LPS O-PS genes are concentrated
in two genetic regions: wbk (which includes genes of gly-
cosiltransferases, enzymes for the synthesis of precursors
and bactoprenol priming, and several insertion sequences
[IS]) and wbo (carrying the wboA and wboB glycosyltrans-
ferase genes), the latter being part of genomic island 2
(GI-2) [9-12]. Other genes coding for glycosyltransferases
and synthesis of precursors are scattered in the genome
[9,13]. Although the causes of the S-R dissociation have
not been completely elucidated, there have been recent
advances in our understanding of the main genetic me-
chanisms involved. In wild-type B. abortus, the spontan-
eous excision of 15.1 kb GI-2 island (which removes the
wboA and wboB loci) by recombination promoted by the
GI-2-encoded integrase (int) is one of the main sources of
S-R dissociation, and identical dissociation mecha-
nisms have been proposed for B. melitensis and B. suis
(Figure 1A) [10]. A similar spontaneous recombination
and excision affects wbkA (a wbk glycosyltransferase gene),
in this case mediated by RecA, which recognizes the flank-
ing wbkA transposases as substrates for homologous re-
combination [14] (Figure 1B). In both cases, the resulting
R mutants carry a chromosomal scar that results from the
release of a circular intermediate (Figure 1A and 1B) that
is lost in subsequent rounds of replication. In addition, a
proportion of R mutants result from random mutations
affecting the manBcore gene and possibly other LPS genes
related to the synthesis of O-PS and core oligosacchar-
ide precursors and their assembly [15]. The R pheno-
type of the B. abortus RB51 vaccine is also known to
relate in part to the disruption of gene wboA of GI-2 by
IS711 (Figure 1D), which indicates the mobility of IS711
as a source of R mutations [16]. Examination of the LPS
genes of B. canis and B. ovis, two naturally R species,
confirms some of the above mechanisms and reveals
additional possibilities for the generation of defective
LPS. B. canis carries a deletion encompassing genes
wbkD and wbkF (Figure 1C) probably generated by a
slipped mispairing mechanism [17]. B. ovis lacks GI-2
(and bears the corresponding genomic scar) and carries
mutations affecting manBcore, wbkF and other wbk
genes (Figure 1E) [10-12,15,17].
Since GI-2 and region wbk are conserved in S brucel-
lae, we hypothesized that GI-2 and wbkA excisions couldbe involved in the S-R dissociation of vaccine Rev 1, and
that the stability of this vaccine could be improved. Here
we show that these two mechanisms account for the ma-
jority of the mutations involved in the S-R dissociation of
this vaccine. We also show that mutation of the int gene
in GI-2 and the IS-sequences flanking wbkA in Rev 1 sta-
bilizes the S phenotype without altering the biologically
relevant characteristics of the vaccine. Accordingly, we
propose the corresponding double GI-2 int and wbkA IS
mutant of Rev 1 as an improved, more stable vaccine
against B. melitensis infection in small ruminants.
Materials and methods
Bacterial strains and culture conditions
The Brucella strains used are listed in Table 1, and the
E. coli strains and plasmids are in Additional file 1. For
S-R dissociation experiments, three lots of commercial
Rev 1 vaccine showing 0%, 5% and 100% of dissociation
(determined by the crystal violet exclusion method, fol-
lowing the standard protocol for vaccine quality con-
trol [8]) were selected from a collection kept in the
Centro de Investigación y Tecnología Agroalimentaria of
Aragón (CITA), Zaragoza, Spain. Bacteria were grown ei-
ther on trypticase soy agar (TSA; Becton Dickinson,
Madrid, Spain), Blood Agar Base number 2 (BAB; Oxoid,
Hampshire, UK) plates (37 °C, 1–5 days) or in trypticase
soy broth (TSB; Becton Dickinson, Madrid, Spain). For
cloning, E. coli was grown in Luria-Bertani broth (LB;
Becton Dickinson, Madrid, Spain) supplemented with
kanamycin (Km; 50 μg/mL) or chloramphenicol (Ch;
20 μg/mL). Subcultures in BAB supplemented with
nalidixic acid (Nx; 25 μg/mL) were used for obtaining the
B. melitensis H38-NxR spontaneous variant used as chal-
lenge strain in vaccine experiments in mice.
Sequence analyses
Confirmation of constructed mutant genotypes and ana-
lysis of manBcore locus in spontaneous R mutants was car-
ried out on PCR fragments by DNA sequencing, using the
dideoxy method at the Sequencing Unit of Centro de
Investigación Médica Aplicada (CIMA, Universidad de
Navarra, Spain). In silico mutants were designed using
the complete sequence of chromosome I of B. melitensis
16 M as template [GenBank: AE008917] [18]. Similarity
searches were performed by BLAST [19] and sequence
alignments by Clustal Omega [20]. In silico restriction
analyses of wbo and wbk regions were performed with
Vector NTI software (Invitrogen, USA).
PCR assays
The primers designed to identify mutations known to affect
the O-PS generating R phenotypes are indicated in Figure 1
and listed in Table 2. In addition, primers BMEI0993F
and BMEI1013R (GI-2 deletion) or BMEI1398F and
Figure 1 (See legend on next page.)
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Figure 1 Genetic organization of regions encoding LPS genes that are susceptible to mutation with a subsequent generation of
R mutants. (A) GI-2 region of B. melitensis and the scar and circular intermediate (wbo genes are omitted in the circular intermediate) resulting from
the int- promoted excision; (B) wbkA region and the corresponding scar and circular intermediate resulting from homologous recombination between
ISBm1 transposases; (C) the wbkFD region of B. melitensis and B. canis (wbkD is annotated as capD in B. canis); (D) wbo locus in B. melitensis and B. abor-
tus RB51 and (E) manBAcore locus in B. melitensis chromosome II with its corresponding mutants showing the deletion and point mutations in manBcore
gene (asterisks). The position of the primers used in the PCR analyses is indicated as P-number of the primer. The ORF annotations are based on the B.
melitensis 16 M genome [GenBank: AE008917 and AE008918] and B. canis chromosome I [GenBank: CP000872].
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chromosomal scars, and primers BMEI0994R and
BMEI1012bF (GI-2 region) or BMEI1400R and
BMEI1409F (wbkA gene) were used for detecting the
circular intermediates. Primers were generated with
Primer3 software [21]. Genomic DNA (gDNA) was
obtained by using standard protocols [22] or boiling
(95 °C, 10 min) either directly from bacterial colonies
grown in TSA plates or from Rev 1 commercial vaccine
vials rehydrated in saline. PCR assays were performed
in a final volume of 25 μL containing 0.2 μg of gDNA,
12.5 pmol of the correspondent primer, 0.2 mM of
dNTPs, 2 mM of MgCl2 and 1U of Immolase DNA
polymerase (Bioline, London, UK). The mixture wasTable 1 Brucella strains used.
Strain Characteristics Source/
reference
B. melitensis
H38
B. melitensis smooth virulent strain; S-LPS CITA
collection
H38-NxR B. melitensis H38 spontaneous mutant
resistant to nalidixic acid; challenge studies
in mice; S-LPS
This work
Rev 1 B. melitensis smooth attenuated reference
vaccine strain; S-LPS
CITA
collection
Rev 1ΔwbkA Rev 1 spontaneous deletion mutant in
wbkA (ORF BMEI1398 and BME1412); R-LPS
This work
Rev 1ΔGI-2 Rev 1 spontaneous deletion mutant in GI-2;
R-LPS
This work
Rev
1ΔISBm1
Rev 1 in-frame deletion mutant in ISBm-1
transposase gene (ORF BMEI1398 and
BME1400); S-LPS
This work
Rev 1Δint Rev 1 in-frame deletion mutant in GI-2
phage-integrase gene (nucleotides int Δ53–
286); S-LPS
This work
Rev 2
(ΔISBm1Δint)
Rev 1 double in-frame deletion mutant in
ISBm-1 transposase and GI-2 phage-
integrase; S-LPS
This work
Rev
1ΔwbkA/c
Rev 1ΔwbkA rough spontaneous mutant
complemented with plasmid pMM14; S-LPS
This work
Rev 1ΔGI-2/
wboAB
Rev 1ΔGI-2 rough spontaneous mutant con-
taining the plasmid pMM76; R-LPS
This work
Rev 1ΔGI-2/c Rev 1ΔGI-2 rough spontaneous mutant
complemented with plasmid pBGI-997-99c;
S-LPS
This work
S-LPS: smooth lipopolysaccharide; CITA: Centro de Investigación y Tecnología
Agroalimentaria of Aragón (Zaragoza, Spain); R-LPS: rough lipopolysaccharide;
GI-2: Genomic Island 2.pre-incubated at 95 °C for 5 min, followed by 30 cycles
(95 °C for 20 s; 60 °C for 30 s; and 72 °C for 1 min) with
a final extension at 72 °C for 5 min. All PCR rounds
were carried out in a Mastercycler gradient PCR ma-
chine (Eppendorf, Hamburg, Germany). Amplicons and
restriction fragments were resolved by electrophoresis
in 1.0-2.0% TBE (45 mM Tris-borate, 1 mM EDTA pH
8.0) agarose gels. All PCR experiments included DNA
from S Rev 1 as a control.
Southern blot
The distribution of IS711 sequences was assessed by
Southern blot using 1–2 μg of AvaI-ClaI double digested
gDNA from B. melitensis Rev 1 related-strains as previ-
ously described [23]. Restriction fragments were resolved
in 1% agarose-TBE at 25 mA for 10 h and probed with
ECL direct-labeled system (GE Healthcare, Waukesha,
WI, USA). IS711 fragment was generated by PCR with
primers 711u and 711d as well as the corresponding GI-2
(~1.4 kb, BMEI0999 primers) and wbkA (332 bp,
BMEI1404 primers) specific DNA probes (Table 2).
Chemiluminiscent detection of the hybridized product
was performed using a commercial kit (GE Healthcare,
Madrid, Spain) and enhanced ECL Films for developing by
conventional photographic methods. Blots were stripped
with 1% SDS at 80 °C for 30 min and EDTA 20 mM at
room temperature for 15 min, and then analyzed for the
presence of GI-2 and wbkA with specific DNA probes.
Mutagenesis
The Rev 1 strain used in these experiments was a vac-
cine seed lot of proved efficacy. It was generously pro-
vided by Dr J.M. Blasco (CITA of Aragón, Spain). For
mutagenesis, a parental Rev 1 clone was selected directly
from colonies grown on agar according to morphology,
size and agglutination criteria previously described [24,25].
A first Rev 1 (ΔISBm1 strain) mutant carrying a deletion
of 872 bp spanning ORFs BMEI1398-1400 (ISBm1
complete transposase) was constructed by allelic exchange
[26]. Briefly, PCR fragments produced with primers pairs
BMEI1401_F1, R2 and BMEI1397_F3, R4 (Table 2) were
ligated by PCR overlap, and the resulting fragment was
cloned into pCR2.1 TOPO (Invitrogen, USA) to produce
plasmid pMM20. The BamHI-NotI fragment of pMM20
was subcloned into plasmid pJQK [27] to generate the
Table 2 List of oligonucleotides used.
Name Sequence (5′→ 3′) Name in Figure 1 Reference
711u cacaagactgcgttgccgacaga [23]
711d catatgatgggaccaaacacctaggg [23]
BMEI0999F cacgatcaaaacgatgccct This study
BMEI0999R ccaaaatgtcctgagcttgg This study
BMEI1404F aagggctggaacctaggaga This study
BMEI1404R aatgacttccgctgccatag This study
BMEI0993F caacatcgcaaagcctgaaa P1 [10]
BMEI1013R cgcaatccagccaatacctg P2 [10]
BMEI0994R atcgtcggcattgtctctct P3 [10]
BMEI1012bF attatccggcggtatgtgag P4 [10]
BMEI1398F gatcttggtatcggcctgtc P5 [14]
BMEI1413R tgcgactttcttcacgattg P6 [14]
BMEI1400R cgctttaatatctcgcgttcc P7 [14]
BMEI1409F ggtcccatcggcatatctt P8 [14]
BMEI1426F ctggagtgtgccgaaagtg P9 This study
BMEI1427R gctgatctcttccgacaagg P10 This study
BMEI0998F ttaagcgctgatgccatttccttcac P11 This study
BMEI0998R gccaaccaacccaaatgctcacaa P12 This study
BMEII0898F tcggcacagcaagctataaa P13 This study
BMEII0912R ggtgtggatattgcgctttc P14 This study
BMEII0899F ccgcctatgcctatacgatg P15 This study
BMEII0899R gcctcatcatccttgtcgat P16 This study
BMEI1401_F1 ttctcgagagcctgaagagc This study
BMEI1401_R2 gccttcgtcgagaaaatgag This study
BMEI1397_F3 ctcattttctcgacgaaggccgtttgcatcaatcagttcg This study
BMEI1397_R4 ctcggctggcagtatctttc This study
BMEI1012_F1 caaagagctaagggcattcg This study
BMEI1012_R2 cgcgaaactttgaagcatct This study
BMEI1012_F3 agatgcttcaaagtttcgcgtctatatcgccggtctgtcc This study
BMEI1012_R4 tttcagtgctttatgacgaaaat This study
F, forward; R, reverse.
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conjugation using E. coli S17-1λpir [28]. Double crossover
transconjugants were selected on polymyxin 1.5 μg/mL
and sucrose 5% plates, and the mutants were identified by
PCR. The same strategy was used to construct a Rev 1Δint
(BMEI1012) non-polar mutant. Two fragments generated
with primer pairs BMEI1012_F1, R2 and BMEI1012_F3,
R4 (Table 2) were ligated by PCR. The resulting fragment
containing a copy of int lacking the nucleotides encoding
amino acids 53–286 was cloned into pCR2.1 TOPO to
produce the plasmid pMM55. Then, the BamHI-XbaI
fragment of pMM55 was subcloned into the plasmid
pJQK to generate the pMM56 suicide vector, which in
turn was transferred to Rev 1 by conjugation, and themutants were identified by PCR. Mutant Rev 1 ΔISBm1
was used to construct the double mutant ΔISBm1Δint
(hereafter Rev 2) using the mutator plasmid pMM56.
Maintenance of the reading frame was verified by sequen-
cing of suicide vectors and of PCR amplified fragments of
the final constructs [26].
Complementation
To confirm the origin of the mutation, spontaneous Rev
1 R strains lacking wbkA were complemented with plas-
mid pMM14, which carries a copy of wbkA [14]. In the
case of spontaneous ΔGI-2 Rev1 R mutants, plasmids
pMM76 (carrying wboA-wboB) or pBGI-997-99c (carry-
ing wboA-wboB plus ORF BMEI0999) were used [29].
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A loop of bacteria previously grown on TSA plates for
72–96 h at 37 °C was transferred to a flask containing
10 mL of TSB, and the flask was incubated until bacteria
reached the stationary phase (37 °C, 72–96 h). An aliquot
of this culture was adjusted to 0.109 of optical density at
750 nm (equivalent to 108 CFU/mL) using sterile TSB and
then diluted 1:100 in the same broth. After incubation for
3–4 days at 37 °C, serial ten-fold dilutions were plated on
TSA, plates were incubated (37 °C, 5 days), and S-R dis-
sociation was assessed by the crystal violet exclusion
method and the R phenotypes confirmed by agglutination
with 0.1% acriflavine [5,8]. Dissociation rate was calculated
as the ratio between the number of R colonies and the
total colony counts. In addition, commercial Rev 1 vaccine
lots were analyzed for dissociation by PCR amplification
(see above) of ΔGI-2 and ΔwbkA chromosomal scars using
DNA obtained directly from vaccine batches reconstituted
as recommended by the manufacturers.
Bacteriological characterization
Brucella spp. and Rev 1-specific phenotypic characteris-
tics were confirmed or assessed by established proce-
dures [24,25]. In addition, growth curves were obtained
in a BioScreen C [30] apparatus. For this, the parental
Rev 1, the Rev 2 double mutant ΔISBm1Δint and the
virulent B. melitensis H38 (as a control) were inoculated
(5 × 106 CFU/well) by triplicate in Bioscreen multi-well
plates containing 250 μL/well of TSB, and the optical
density was read at 600 nm wavelength (O.D.600) at
10 min intervals, until to reach the stationary phase.
LPS characterization
The S or R nature of LPS of the mutant and complemented
strains was analyzed by Western blot of SDS-proteinase
K extracts using the serum of a rabbit immunized with
B. melitensis 16 M [9,31]. Purified S and R-LPS obtained as
described previously [9,31] were used as controls.
Experiments in mice
The biological properties of Rev 1ΔISBm1Δint mutant
(Rev 2) determined in comparison with the reference Rev
1 vaccine were virulence and protective efficacy in the
mouse model. Female BALB/c mice 7–8 weeks old were
purchased from Charles River International (France) and
accommodated in the animal facilities of CITA (registra-
tion code ES/50-2970-12005) or Universidad Pública de
Navarra (UPNA; registration code ES/31-2016-000002
CR-SU-US) for 1–2 weeks before starting and during the
assays, with water and food ad libitum. Animal handling
was performed in compliance with current European and
national (RD 53/2013) regulations, following the FELASA
and ARRIVE guidelines, and with the approval of the
CITA or UPNA Animal Experimentation Committees andlocal Government authorization (approval reference num-
ber R130/2012). Mice inoculations were carried out with
0.1 mL of bacterial suspension previously adjusted to an
optical density at 600 nm of 0.170 (approximately 1 ×
109 CFU/mL) and then diluted to the appropriate dose
(see below) in sterile phosphate buffered saline [32]. For
virulence, groups of 30 mice each were inoculated intra-
peritoneally with 1 × 105 CFU/mouse of Rev 2 or Rev 1
attenuated strains. As a control, an additional group of
30 mice were inoculated similarly with the virulent
B. melitensis H38 reference strain. Spleen weights and
viable counts (n = 5) were determined at 1, 3, 6, 9, 12 and
15 weeks post-inoculation as described previously [32]. The
identity of the spleen isolates was confirmed by PCR, and
the constancy of the typical Rev 1 phenotypic features con-
firmed throughout the experiments. Spleen weights were
expressed as the mean and SD (n = 5) of grams/spleen and
the level of spleen infections as mean ± SD (n = 5) of indi-
vidual log10 CFU/spleen at the indicated times.
Efficacy studies were carried out in groups of 5 BALB/c
mice each vaccinated subcutaneously with 1 × 105 CFU/
mouse of Rev 2 or Rev 1 (parental control), or with
0.1 mL of phosphate buffered saline (pH 6.85) as the pla-
cebo vaccinated control. Four weeks after vaccination, all
mice were challenged intraperitoneally with 1 × 104 CFU/
mouse of B. melitensis H38-NxR, and the number of chal-
lenge bacteria in spleens was determined 2 weeks after-
wards [32]. Differentiation between challenge and residual
vaccine bacteria was performed by double plating on BAB
and BAB supplemented with Nx 25 μg/mL. The results
were expressed as the mean and SD (n = 5) of the log10 of
B. melitensis H38-NxR/spleen. In a previous work, the
virulence in mice of the B. melitensis H38-NxR challenge
strain used in this work was found to be indistinguishable
from that of the reference H38 and 16 M strains [9].
In both virulence and protection experiments, statis-
tical comparisons of means were performed by a one-
way ANOVA followed by the Fisher’s Protected Least
Significant Differences tests [32].
Results
Deletions involving GI-2 and wbkA are the major causes
of S-R dissociation of B. melitensis Rev 1
As a first approach to determine the dissociation mecha-
nisms operating in Rev 1, we searched for ΔGI-2 and
ΔwbkA chromosomal scars, for deletions in wbkF and
wbkD, insertion of IS elements on wboA and manBcore
mutations (Figure 1) in Rev 1 spontaneous R mutants.
To this end, we studied a collection of 32 R Rev 1 iso-
lates (previously obtained by repeated plating on TSA
and crystal violet and acriflavine agglutination screening)
and characterized them by PCR using the primers
described in Table 1. We found 8 ΔGI-2 and 3 ΔwbkA
mutants, but we did not detect redundancy or other
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including point mutations in manBcore in the remaining
21 mutants.
To confirm that the above observations corresponded in
fact to the expected GI-2 or wbkA deletions and O-PS de-
fects, we first characterized Rev 1 R mutants by IS711-fin-
gerprinting using DNA probes specific for the wbkA and
GI-2 loci. We found that, as predicted, ΔGI-2 and ΔwbkA
Rev 1 mutants lacked the IS711 bands of 4.2 and 3.8 kb,
respectively (Figure 2A). Second, we examined the LPS
phenotype by Western blot. Figure 2B shows that the
LPS of the Rev 1 mutants lacked the O-PS. Third, we
performed complementation experiments in eleven RFigure 2 Genetic and phenotypic characterization of spontaneous Re
spontaneous R variants with IS711 (left panel), wbkA (center panel) and GI2
B. melitensis Rev 1 and ΔwbkA but not ΔGI-2, the signal at 4.2 kb correspon
fragments with molecular masses lower than 3.8 kb were omitted. (B) Wes
and the corresponding complemented strains probed with anti-LPS antibomutants using plasmids encoding the wbkA (pMM14) or
the tandem wboA-wboB of GI-2 (pMM76). We found that
the 3 spontaneous Rev 1 ΔwbkA R isolates were comple-
mented with plasmid pMM14 (a representative result can
be seen in Figure 2B, lane ΔwbkA/c). However, we repeat-
edly failed to complement the Rev 1 ΔGI-2 R isolates with
plasmid pMM76 (not shown). Rajashekara et al. [29] dem-
onstrated that artificially constructed B. melitensis ΔGI-2
R mutants could be reverted to S phenotype with a plas-
mid (pBGI-997-99c) bearing wboA and wboB plus ORF
BMEI0999. Using this approach, we could revert 8 spon-
taneous Rev 1 ΔGI-2 R isolates (a representative result can
be seen in Figure 2B, lane ΔGI-2/c). These results showv 1 R mutants. (A) Southern blot analysis of B. melitensis Rev 1
BMEI0999 (right panel) as probes. Note that, for the IS711 probe and
ds to two bands (predicted MW 4.2 and 4.14 kb). For simplicity,
tern blot of purified R-LPS and S-LPS, Rev 1, wbkA and GI-2 R mutants
dies.
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carried more than one R-linked mutation and, in addition,
support the hypothesis that the protein encoded by
BMEI0999 plays a role in O-PS synthesis. In summary, the
results showed that two previously described dissociation
mechanisms, int-dependent (for GI-2 excision) and wbk
IS-RecA dependent (for wbkA), are actually active in Rev 1.
Finally, to study whether ΔGI-2 and ΔwbkA excisions
occurred during vaccine manufacturing, we examined
three commercial Rev 1 lots with different levels of dis-
sociation (see Material and methods). We identified the
GI-2 and wbkA chromosomal scars in these commercial
preparations (not shown) and, interestingly, the lot with
the highest dissociation rate (almost 100%) presented
both chromosomal scars. Considering these results and
those of the above-described experiments, we concluded
that GI-2 and wbkA deletions occur repeatedly in
batches during manufacturing despite the precautions
taken to minimize S-R dissociation.
The S-R dissociation of B. melitensis Rev 1 is reduced by
mutation of GI-2 int and ISBm1 transposase flanking wbkA
We have previously shown that disruption of GI-2
phage-related integrase int gene reduces the dissociationFigure 3 Stabilization of regions GI-2 and wbkA by deletion of appropr
(ΔISBm1) and both (Rev 2). (A) PCR detection of the chromosomal scar and
excision (right panel). (B) S-R dissociation rates.rate of B. abortus by stabilization of GI-2 [10]. To test
whether this also occurs in B. melitensis Rev 1, we con-
structed mutant Rev 1Δint by in-frame deletion of GI-2
int (see Material and Methods). Similarly, we have previ-
ously shown that the excision of the 5.5 kb fragment car-
rying wbkA is caused by homologous recombination
mediated by RecA and the wbkA-flanking IS [14]. Thus,
we also constructed mutant Rev 1ΔISBm1, which lacks
one of the wbkA-flanking ISBm1 copies. Characterization
by PCR demonstrated only the scar and circular inter-
mediate corresponding to GI-2 excision in Rev 1ΔISBm1
(Figure 3A), showing the stabilization of wbkA. Con-
versely, Rev 1Δint displayed the scar and circular inter-
mediate corresponding to an excision of the wbkA
(Figure 3A). To stabilize both genetic regions, we con-
structed the Rev 1ΔISBm1Δint double mutant (Rev 2) on
the Rev 1ΔISBm1 background. As expected, Rev 2 did not
show evidence (scars or circular intermediates) of GI-2 or
wbkA excision events by PCR (Figure 3A) even in experi-
ments with high amounts of template DNA.
Using the above mutants and the parental Rev 1 and
B. melitensis H38 as references, we assessed the import-
ance of the corresponding genetic mechanisms in the
frequency of the S-R dissociation of Rev 1. To this end,iate section of GI-2 phage-related integrase (Δint), wbkA-flanking IS
circular intermediate resulting from (GI-2 excision (left panel) and wbkA
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and counted the proportions of R bacteria using the
crystal violet exclusion method (see Material and methods,
S-R dissociation assessment). While dissociation of strain
H38 was beyond detection under the experimental condi-
tions, Rev 1 showed dissociation rates of 4.27 ± 1.34%
(Figure 3B). In contrast, the single mutants displayed
lower (p < 0.0001) dissociation rates than Rev 1. These
dissociation rates were significantly (p < 0.01) lower for
Rev 1Δint (0.38 ± 0.33) than for Rev 1ΔISBm1 (1.70 ±
0.38). Consistent with the prediction, the double mutant
Rev 2 showed the lowest dissociation rates (0.17 ± 0.13%).
Therefore, under these experimental conditions, GI-2 and
wbkA stabilization resulted in an approximately 25-fold
(i.e. about 95%) decrease in dissociation.Figure 4 Genetic stabilization in Rev 2 does not alter the in vitro grow
growth kinetics; (B) Residual virulence (log CFU/spleen); (C) Spleen weights
BALB/c mice. Statistical comparison of means was performed by one-way A
(PBS group).Stabilization of the S phenotype does not alter the
properties of Rev 1 in vitro or in mice
Standard bacteriological characterization demonstrated
that Rev 1ΔISBm1, Rev 1Δint and Rev 2 conserved the
phenotypic markers that are characteristic of Rev 1,
namely: S phenotype (demonstrated by reactivity with
anti-S antibodies and by the crystal violet and acriflavine
tests), inhibition by 5 IU/mL penicillin, resistance to
2.5 μg/mL of streptomycin, and comparatively small col-
ony size (1–1.2 mm diameter after 5 days of incubation
at 37 °C) [24,25]. Since the latter feature (i.e. slow
growth) is a particularly important Rev 1 property ([33];
see also below), we compared the growth curves of Rev
1, Rev 2 and the wild-type B. melitensis H38 reference
strain. As can be seen in Figure 4A, Rev 1 and Rev 2th and vaccine properties of Rev 1 reference vaccine. (A) In vitro
; and (D) Efficacy against a virulent B. melitensis virulent challenge, in
NOVA and Fisher’s PLSD test: aP < 0.005 vs. unvaccinated control
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retarded with respect to B. melitensis H38.
We completed the characterization of Rev 2 by studying
whether the critical biological properties of Rev 1 (i.e. re-
sidual virulence and efficacy against virulent infection)
were maintained in Rev 2. For this purpose, we used the
established mouse model for brucellosis vaccine control
[34], which is useful in discriminating Rev 1 vaccine lots of
inappropriate residual virulence and immunogenicity [25].
Rev 2 showed a behavior almost identical to that of Rev 1
in this model. In virulence assays, both strains persisted
similarly and less than the virulent B. melitensis H38 strain
(Figure 4B). Likewise, Rev 1 and Rev 2 induced a similarly
reduced splenomegaly (Figure 4C). Finally, Rev 2 was as
protective as Rev 1 against a challenge infection with the
full-virulent B. melitensis H38-NxR strain (Figure 4D).
Discussion
A major practical aspect of vaccine production is quality
control. Because of the well-known genetic instability of all
brucellae in vitro [34], control is particularly critical in
brucellosis vaccines. Therefore, a manufacturing seed-lot
system [33] has been adopted to reduce genetic drifts in-
cluding the appearance of R types. In addition, control of
every single batch includes the assessment of colony S
phase and morphology [24]. As confirmed here by com-
parison with B. melitensis H38, dissociation of B. melitensis
Rev 1 into S and R forms is particularly troublesome and,
although the reasons for this difference between the viru-
lent bacteria and the vaccine are not known, it is possible
to indicate probable causes. Our results indicate that the
genetic mechanisms operating in Rev 1 dissociation are
those described before for other S strains and, therefore, it
seems unlikely that this Rev 1 trait follows particular gen-
etic characteristics of this vaccine. A more probable possi-
bility is suggested by the well-known fact that oxygen
limitation and other conditions causing energy shortage
facilitate the establishment of Brucella R variants [35]. Ac-
cordingly, we have proposed [14] that mutants not synthe-
sizing the costly O-PS are more competitive when energy
shortage and no selective pressure to maintain the O-PS
concur and that, under these circumstances, the excision
of GI-2 promoted by the phage-related integrase int gene
and the deletion of wbkA by homologous recombination
become prominent. In the case of Rev 1, it is known that
this vaccine carries a defect in ribosomal protein S12 that
relates to its streptomycin resistance [36]. In Salmonella
Typhimurium, a similar S12 mutation causes streptomycin
resistance, increased rates of ribosomal proofreading and,
as a result, decreased rates of protein synthesis, reduced
bacterial growth and attenuation [37]. Therefore, it seems
likely that the S12 defect in Rev 1 is a major cause of re-
duced fitness and growth rates (and attenuation), both of
which could be compensated for by the reduction inenergy expenditure caused by at least (see below) the loss
of O-PS, thereby favoring the growth of R mutants. In fact,
Rev 1 is characterized by a small colony size and the S-R
dissociation is often accompanied by the appearance of lar-
ger colonies not appropriate for vaccine use [25].
Although we investigated other known R-generating
mutations, we only detected the GI-2 and wbkA deletions
in Rev 1. Turse et al. [15] have shown that point mutations
on manBcore, a gene required for the complete synthesis of
O-PS [9], are a cause of spontaneous appearance of R vari-
ants, which have been isolated from infected macrophages
and mice [15]. We failed to reveal any point mutations in
this locus by sequencing manBcore in the 21 R strains that
did not show either wbkA or GI-2 deletions. Since Turse
et al. performed their experiments with B. abortus 2308
and B. melitensis 16 M and recovered the R mutants using
agar plates saturated with Bk2 phage (specific for the S-
phase), it seems that the discrepancies could be explained
by the use of different experimental conditions. Concern-
ing the genetic mechanisms, we observed that inactivation
of the GI-2 integrase had a more significant effect on O-
PS stability. This may reflect a higher instability of this
region related to the activity of the integrase and/or to the
concomitant loss of Omp25b (a major outer membrane
protein encoded in GI-2 [11]), since the ensuing reduction
in biosynthetic expenditures would increase competitive-
ness in vitro. Another possibility is suggested by the fact
that recombinases like the one coded for by GI-2 int are
able to identify secondary target repeat sequences promot-
ing the excision of unrelated fragments [38]. Therefore,
the GI-2 integrase could theoretically take part in other
events leading to the R phenotype. This work also shows
that mutations other than those described thus far also
cause the appearance of R types. This is shown by the fact
that dissociation was not completely prevented in Rev 2
strain. Further investigations are necessary for a full un-
derstanding of the mutation paths that affect the O-PS in
Brucella.
Because the underlying mechanisms were known, we
could abrogate the GI-2 and wbkA deletions and generate
a more stable Rev 2 strain. Indeed, as shown by the experi-
mental results presented here, the absence of large sec-
tions of the DNA sequences involved in this deletion
events make highly unlikely the possibility that Rev 2
could revert to an anomalously high S-R dissociation rate.
Thus, the genetic strategy described here represents a
complement to the empirical methods currently used in
the production of smooth Brucella vaccines for the
stabilization of smooth phenotype. Although the compari-
son between the virulent H38 strain and Rev 1 showed dif-
ferences in both growth and S-R dissociation rates, our
results demonstrate that the increased S-R dissociation is
not linked to attenuation of Rev 1 in the mouse model, as
it might be expected from the characteristic attenuation of
Mancilla et al. Veterinary Research 2013, 44:105 Page 11 of 12
http://www.veterinaryresearch.org/content/44/1/105Brucella R mutants. As discussed above, the reduced fit-
ness probably caused by the S12 mutation that is mani-
fested by the lower growth rates is a more likely cause of
attenuation. Rev 2 conserved this characteristic and also
the relevant biological properties of Rev 1 in the mouse
model. Although this model represents the best laboratory
control for the in vivo properties of Rev 1 [33], experi-
ments in the natural hosts are clearly necessary to prove
that Rev 2 retains all the properties that have made Rev 1
a succesful vaccine.
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